Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 075 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5 AND LACTATED RINGER S IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.
Potassium chloride provides potassium ions for maintenance of electrolyte balance and repolarization of cell membranes. Dextrose 5% provides caloric supplementation and may enhance potassium uptake into cells via insulin-mediated mechanisms. Lactated Ringer's solution provides isotonic crystalloid fluid, electrolytes (sodium, calcium, lactate), and buffer (bicarbonate precursor) to maintain intravascular volume and acid-base balance.
Intravenous administration at a rate not exceeding 10 mEq/hour of potassium chloride; typical adult dose is 20-40 mEq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.
Intravenous infusion: 10–20 mEq/hour, not to exceed 20–40 mEq in 4 hours or 150 mEq per 24 hours. Rate: max 10 mEq/hour (1 mEq/mL concentration).
None Documented
None Documented
Potassium has a biphasic elimination: distribution half-life ~1 hour, terminal elimination half-life ~12 hours in normal renal function. Clinical context: Half-life extends significantly in renal impairment, requiring dose adjustment.
Potassium does not have a classical elimination half-life as it is an electrolyte with complex distribution and regulation. After a single IV dose, plasma levels decline rapidly due to redistribution, with an initial distribution half-life of about 1 hour. The terminal phase reflects slow equilibration with total body stores and is influenced by renal function; in anephric patients, the effective half-life is extended significantly.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Minor fecal elimination accounts for ~10%. Renal excretion is influenced by aldosterone, acid-base status, and potassium intake.
Potassium is primarily excreted renally (90%) via glomerular filtration and active secretion in the distal tubule; approximately 10% is lost in feces. In patients with normal renal function, urinary excretion is increased when intake is high. In the presence of renal impairment, elimination is decreased, leading to hyperkalemia risk. Dialysis (hemodialysis or peritoneal dialysis) can remove potassium.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement